Showing 1 - 4 results of 4 for search 'Igor Smolenov', query time: 0.02s Refine Results
  1. 1
    SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines

    SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines by Camilo C. Roa, Mari Rose A. de Los Reyes, Eric Plennevaux, Igor Smolenov, Branda Hu, Faith Gao, Hannalyn Ilagan, Donna Ambrosino, George Siber, Ralf Clemens, Htay Htay Han

    Published 2024-12-01
    Get full text
    Article
  2. 2
    Boosting with adjuvanted SCB-2019 elicits superior Fcγ-receptor engagement driven by IgG3 to SARS-CoV-2 spike

    Boosting with adjuvanted SCB-2019 elicits superior Fcγ-receptor engagement driven by IgG3 to SARS-CoV-2 spike by Wonyeong Jung, Dansu Yuan, Benjamin Kellman, Isabela Garrido da Silva Gonzalez, Ralf Clemens, Eveline Pipolo Milan, Eduardo Sprinz, José Cerbino Neto, Igor Smolenov, Galit Alter, Ryan P. McNamara, Sue Ann Costa Clemens

    Published 2024-01-01
    Get full text
    Article
  3. 3
    A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults

    A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults by Antonios O. Aliprantis, Christine A. Shaw, Paul Griffin, Nicholas Farinola, Radha A. Railkar, Xin Cao, Wen Liu, Jeffrey R. Sachs, Christine J. Swenson, Heather Lee, Kara S. Cox, Daniel S. Spellman, Colleen J. Winstead, Igor Smolenov, Eseng Lai, Tal Zaks, Amy S. Espeseth, Lori Panther

    Published 2021-05-01
    Get full text
    Article
  4. 4
    Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12–17 year-old adolescents

    Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12–17 year-old adolescents by Pio Lopez, Lulu Bravo, Erik Buntinx, Charissa Borja-Tabora, Hector Velasquez, Edith Johana Rodriquez, Camilo A. Rodriguez, Josefina Carlos, May Emmeline B. Montellano, Edison R. Alberto, Milagros Salvani-Bautista, Yung Huang, Branda Hu, Ping Li, Htay Htay Han, Carmen Baccarini, Igor Smolenov

    Published 2023-01-01
    Get full text
    Article

Search Tools: